Home » With three debuts in two weeks, HKEX's biotech IPO market remaining strong

Looking to read the full article? Subscribe to BioWorld.

With three debuts in two weeks, HKEX's biotech IPO market remaining strong

November 1, 2019

BEIJING – After Suzhou, China-based Ascentage Pharma Group International launched a $53 million IPO on the Hong Kong Stock Exchange (HKEX) Monday, Tot Biopharm International Co. Ltd., also from Suzhou, and Sinomab Bioscience Ltd., of Hong Kong, will also debut on the bourse to reap as much as $87 million and $223.1 million, respectively, in the following two weeks.

BioWorld Financings

Already a subscriber? Sign in

Popular Stories

Bioworld MedTech’s Oncology Extra
BioWorld MedTech
Keeping you up to date on recent developments in oncology.
FDA gives thumbs up to Cochlear’s implantable bone conduction hearing system
BioWorld MedTech
The U.S. FDA has cleared Cochlear Ltd.’s newest cochlear implant, the Osia 2 system, an active implantable bone conduction hearing system. Unlike Cochlear’s...
Analysis by U.K. startup Medbelle highlights extent of drug pricing disparity
BioWorld
LONDON – It’s no secret that American citizens pay the most for drugs, but the extent of the disparity is laid bare in a new index of the prices of 13 medicines...
Buoyed by optimism and love of family, former FDA chief Frank Young leaned into storms
BioWorld
Commissioner of the FDA for five years starting in 1984, Frank Young relished his position “at the vortex of controversy” as he sought to deal with the AIDS...
Biopharma companies continue their strong momentum in November
BioWorld
After being in the doldrums for the majority of the year, public biopharmaceutical companies, it appears, have turned the corner and are now on a major upswing.

cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.